PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.43%
R&D growth while AVXL reduces spending. John Neff would investigate strategic advantage.
12.93%
G&A growth while AVXL reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
5.37%
Other expenses growth while AVXL reduces costs. John Neff would investigate differences.
14.34%
Operating expenses growth while AVXL reduces costs. John Neff would investigate differences.
14.34%
Total costs growth while AVXL reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
5.37%
D&A growth while AVXL reduces D&A. John Neff would investigate differences.
-16.61%
EBITDA decline while AVXL shows 52.18% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-14.34%
Operating income decline while AVXL shows 52.20% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-295.23%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-20.40%
Pre-tax income decline while AVXL shows 52.10% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.40%
Net income decline while AVXL shows 51.67% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-19.61%
EPS decline while AVXL shows 51.76% growth. Joel Greenblatt would examine position.
-20.61%
Diluted EPS decline while AVXL shows 51.76% growth. Joel Greenblatt would examine position.
0.76%
Share count change of 0.76% while AVXL is stable. Bruce Berkowitz would verify approach.
No Data
No Data available this quarter, please select a different quarter.